ArticleScientific reports2026
Small-nucleolar RNA host gene3 (SNHG3) and leukemia-associated non-coding IGF1R activator RNA 1 (LUNAR1) correlated with CRC patients' clinical features: a step-toward ncRNA-precision.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Notch-signaling is implicated in tumorigenesis as well as Notch-associated long non-coding RNAs (lncRNAs) small nucleolar RNA host gene3 (SNHG3) and leukemia-associated non-coding IGF1R activator RNA 1 (LUNAR1) are highly expressed in various malignant tissues including colorectal cancer (CRC). However, the clinical and prognostic utility of these lncRNAs in CRC patients' blood is still lacking. The aim of this study was to assess the expression patterns of circulatory Notch-associated lncRNAs SNHG3 and LUNAR1 and to explore their relevance for CRC follow up and risk assessment. SUBJECT AND
methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was used to quantify the expression levels of SNHG3 and LUNAR1 in sera of 70 Egyptian CRC patients' and to compare them with 26 age- and sex-matched apparently healthy volunteer control group.
resultsSerum fold-change expression of SNHG3 and LUNAR1 were up-regulated in CRC patients compared to the apparently healthy controls (p < 0.0001). SNHG3 lncRNA fold expression levels were positively correlated with advanced CRC stage (III-IV) (p = 0.0175) being highly related to poorer clinicopathological features of CRC patients including extensive tumor invasion (p = 0.0046), vascular invasion (p = 0.0015), and lymph node metastasis (p = 0.0175). Likewise, LUNAR1 lncRNA fold-expression level was significantly positively associated with larger tumor size (p = 0.0033) and deeper tumor invasion (p = 0.042). The two lncRNAs had higher discriminative utility than either CEA or CA19-9 per the receiver operating characteristic (ROC) curve, with higher sensitivities and specificities (p < 0.0001). A significant positive correlation between SNHG3 and LUNAR1 lncRNAs fold expressions (r = 0.4615, p < 0.0001).
conclusionSNHG3 and LUNAR1 might be useful non-invasive bio-molecular markers for CRC monitoring. Being correlated with poorer CRC patients' clinical features, SNHG3 and LUNAR1 lncRNAs might constitute potential putative therapeutic targets for CRC, per identified downstream genes or proteins in silico, a step toward ncRNA-based precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.